Skip to main content

Fiscal Wizard · Single-issue tearsheet

MNKD / Jun 22, 2026 Run #7662

MNKD

MannKind Corporation

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Composite verdict

F 27.3 / 100
Bearish setup · Reversal 12 drivers · 5 gates blocking
  • Williams %R
  • Volume Climax
  • Pin Bar
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 190th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 21 signals100% Bear
Momentum Neutral 50Mean-reversion Bearish 7

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from
Asset value $-0.17Earnings power value $0.20Price $3.94

Priced above its no-growth earnings power value ($0.20/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

54.0 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Asset Turnover 100
OCF to Net Income 0
Days Sales Outstanding 91
Cash Conversion 0
Revenue Growth (YoY) 89
Earnings Yield 0

Technicals Bearish

0.5 / 100

Bearish setup leads (Williams %R, Volume Climax, Pin Bar); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Williams %R 9
Volume Climax 12
Pin Bar 16

Risk Gates

5 blocking 7 caution

5 guards active, 19 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Beneish M-Score Blocking

Bottom-band Beneish M blocks bullish signals — accounting-quality risk.

Net Debt / EBITDA Blocking

High net debt / EBITDA blocks bullish signals — credit-leverage risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for MNKD.